Mitozolomide

Mitozolomide

Systematic (IUPAC) name
3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
Identifiers
CAS Number	85622-95-3
ATC code	none
PubChem	CID 71766
ChemSpider	64805
UNII	E3U7286V3W
ChEMBL	CHEMBL435951
Chemical data
Formula	C7H7ClN6O2
Molar mass	242.622 g/mol
SMILES NC(=O)c1ncn2C(=O)N(CCCl)\N=N/c12
InChI InChI=1S/C7H7ClN6O2/c8-1-2-14-7(16)13-3-10-4(5(9)15)6(13)11-12-14/h3H,1-2H2,(H2,9,15) Key:QXYYYPFGTSJXNS-UHFFFAOYSA-N
(what is this?)  (verify)

Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.

Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.^[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.^[2]

References

1. Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA (February 2000). "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide" (PDF). Cancer Gene Ther 7 (2): 233–9. doi:10.1038/sj.cgt.7700120. PMID 10770631.
2. Newlands ES, Blackledge GR, Slack JA, et al. (February 1992). "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)". Br J Cancer 65 (2): 287–91. doi:10.1038/bjc.1992.57. PMC 1977719. PMID 1739631.